Streetbeat News

Revenues

NIO

NIO reported a Q3 EPS of $(0.31), a slight decrease from $(0.30) YoY. However, sales increased significantly to $2.61B from $1.83B YoY.

Portfolio Pulse from Benzinga Newsdesk

December 05, 2023 | 9:34 am

HPQ

HP Inc. (NYSE:HPQ) CFO Marie Myers highlighted the success of the company's subscription-based model, particularly the Instant Ink service, which has over 11 million subscribers. This model has improved margins, with the Printing division's margin increasing from 14.8% in fiscal 2020 to 18.9% in fiscal 2023. The subscription service and Smart Tank hardware now account for 60% of total shipments, indicating a strategic shift in HP's business model in response to declining global print volumes.

Portfolio Pulse from Benzinga Neuro

December 05, 2023 | 7:52 am

AAPL

A check signed by Apple Inc co-founder Steve Jobs in 1976 is expected to fetch over $20,000 at auction. The check, which references the 'Apple Computer Company,' is a rare collectible as Jobs was known for rarely giving autographs. In the past, items signed by Jobs have sold for high amounts, with a letter declining an autograph request selling for $479,939 in 2021. The auction for the check is currently active with bids exceeding $22,000. Radio Shack, mentioned in the check's history, filed for bankruptcy in 2015.

Portfolio Pulse from Benzinga Neuro

December 05, 2023 | 6:13 am

EWA

Australia's current account for Q3 reported a deficit of 0.2 billion, contrasting with the estimated surplus of 3.1 billion and the revised prior surplus of 7.8 billion.

Portfolio Pulse from Benzinga Newsdesk

December 05, 2023 | 5:57 am

EWU

The U.K. BRC Retail Sales Monitor reported a year-over-year increase of 2.6% for November, matching the previous figure and slightly above the 2.5% estimate.

Portfolio Pulse from Benzinga Newsdesk

December 05, 2023 | 5:55 am

BRK

BYDDF

TSLA

VWAGY

Chinese EV manufacturer BYD Co. (OTC:BYDDF) faces a $12 billion selloff due to concerns over its sales targets and smart-car capabilities. The company's shares dropped 12% in November, with doubts cast by competition from Huawei and a volatile market. Despite record sales, BYD's growth is questioned, and Warren Buffett's Berkshire Hathaway (NYSE:BRK) has reduced its stake. The EU's probe into Chinese EV subsidies and a surge in short interest in BYD shares add to the challenges. BYD's market cap gap with Tesla (NASDAQ:TSLA) despite similar revenues and sales also raises analyst concerns.

Portfolio Pulse from Benzinga Neuro

December 05, 2023 | 4:47 am

TTWO

Rockstar Games, a subsidiary of Take Two Interactive Software Inc (NASDAQ:TTWO), released the official trailer for 'Grand Theft Auto VI' (GTA 6), confirming a 2025 release and introducing the first female lead, Lucia. The trailer, which was moved up due to a leak, showcases Vice City, social media integration, and hints at teamwork in the game's narrative. Take-Two Interactive has hinted at significant financial gains expected from the game's release between April 2024 and March 2025.

Portfolio Pulse from Franca Quarneti

December 05, 2023 | 12:38 am

JOAN

Joann Inc. (NASDAQ:JOAN) stock dropped in after-hours trading following its Q3 earnings report. The company met analyst expectations with a loss of 21 cents per share, a significant decrease from the prior year's earnings. Quarterly sales of $539.80 million fell short of the $547.20 million estimate and were down 4.09% year-over-year. E-commerce sales grew by 11.5%, but operational cash use increased and free cash flow decreased. Joann announced a cost reduction target of $225 million under its Focus, Simplify and Grow initiative. Full-year 2024 Net Sales are expected to decrease by 1-2%. Shares were down 13.48% at $0.89 in after-hours trading.

Portfolio Pulse from Ryan Gustafson

December 04, 2023 | 10:14 pm

NPCE

NeuroPace has entered into a strategic collaboration to provide biomarker monitoring and data analysis capabilities using its RNS System. A clinical-stage biotechnology company will pay NeuroPace up to $3.7 million over two years for non-exclusive access to these services for its clinical trial patients.

Portfolio Pulse from Benzinga Newsdesk

December 04, 2023 | 10:09 pm

JNJ

The U.S. FDA has granted Breakthrough Therapy Designation (BTD) to Johnson & Johnson's TAR-200 for the treatment of high-risk non-muscle-invasive bladder cancer (HR-NMIBC). TAR-200 is an investigational targeted releasing system for sustained local release of gemcitabine. The designation is based on data from the ongoing Phase 2b SunRISe-1 study, which also evaluates cetrelimab, a PD-1 monoclonal antibody. The BTD aims to expedite the development and review of treatments for serious conditions showing substantial improvement over existing therapies.

Portfolio Pulse from Benzinga Newsdesk

December 04, 2023 | 9:33 pm